Angiodysplasia medical therapy

Jump to navigation Jump to search

Angiodysplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Angiodysplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Angiodysplasia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Angiodysplasia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Angiodysplasia medical therapy

CDC on Angiodysplasia medical therapy

Angiodysplasia medical therapy in the news

Blogs on Angiodysplasia medical therapy

Directions to Hospitals Treating Angiodysplasia

Risk calculators and risk factors for Angiodysplasia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nikita Singh, M.D.[2]

Overview

Treatment is not required for incidentally found, asymptomatic, non-bleeding lesions. However, it is considered for non-bleeding angiodysplasia with symptoms of occult or overt GI bleed. The invasiveness of therapy depends on clinical severity of anemia, hemodynamic stability and recurrence of symptoms. Although endoscopic techniques are the first choice, hormonal therapy, thalidomide and octreotide are the pharmacological options that have been tried for patients with significant co-morbidities who cannot undergo invasive procedures.

Medical Therapy

  • Pharmacological options like hormonal therapy, thalidomide, and octreotide have been tried in patients with significant co-morbidities who cannot undergo invasive procedures.
  • Studies have shown hormonal therapy with ethinylestradiol and norethisterone vs placebo have no difference in outcomes.[1] However, a few case series have shown positive results regarding the efficacy of hormonal therapy in chronic renal failure patients.[2]
  • Thalidomide inhibits angiogenesis by inhibiting vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis.[3] It has been reported to be effective in the management of chronic bleeding from angiodysplasia as well as reduction in the number and size of lesions in numerous.[4][5][6][7]
  • Long-acting octreotide has been used to treat chronic bleeding due to angiodysplasia in elderly patients.[8]

Endoscopic Therapy

  • Endoscopic techniques are the therapy of choice for angiodysplasia.
  • Argon plasma coagulation (APC): Most widely used endoscopic method for the treatment of angiodysplasia that uses high frequency electric current and ionised argon gas.[9]

References

  1. Junquera F, Feu F, Papo M, Videla S, Armengol JR, Bordas JM; et al. (2001). "A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia". Gastroenterology. 121 (5): 1073–9. doi:10.1053/gast.2001.28650. PMID 11677198.
  2. Bronner MH, Pate MB, Cunningham JT, Marsh WH (1986). "Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial". Ann Intern Med. 105 (3): 371–4. doi:10.7326/0003-4819-105-3-371. PMID 3488703.
  3. Chen HM, Ge ZZ, Liu WZ, Lu H, Xu CH, Fang JY; et al. (2009). "[The mechanisms of thalidomide in treatment of angiodysplasia due to hypoxia]". Zhonghua Nei Ke Za Zhi. 48 (4): 295–8. PMID 19576118.
  4. Heidt J, Langers AM, van der Meer FJ, Brouwer RE (2006). "Thalidomide as treatment for digestive tract angiodysplasias". Neth J Med. 64 (11): 425–8. PMID 17179574.
  5. Almadi M, Ghali PM, Constantin A, Galipeau J, Szilagyi A (2009). "Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review". Can J Gastroenterol. 23 (9): 625–31. doi:10.1155/2009/862816. PMC 2776553. PMID 19816627.
  6. Kamalaporn P, Saravanan R, Cirocco M, May G, Kortan P, Kandel G; et al. (2009). "Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series". Eur J Gastroenterol Hepatol. 21 (12): 1347–50. doi:10.1097/MEG.0b013e32832c9346. PMID 19730385.
  7. Bauditz J, Lochs H, Voderholzer W (2006). "Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide". Endoscopy. 38 (10): 1036–9. doi:10.1055/s-2006-944829. PMID 17058171.
  8. Orsi P, Guatti-Zuliani C, Okolicsanyi L (2001). "Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract". Dig Liver Dis. 33 (4): 330–4. doi:10.1016/s1590-8658(01)80087-6. PMID 11432511.
  9. Vargo JJ (2004). "Clinical applications of the argon plasma coagulator". Gastrointest Endosc. 59 (1): 81–8. doi:10.1016/s0016-5107(03)02296-x. PMID 14722558.

Template:WS Template:WH